LFM-A13 is a potent BTK, JAK2, PLK inhibitor that inhibits the activity of BTK, Plx1, and PLK3 with IC50 values of 2.5 μM, 10 μM, and 61 μM, respectively. LFM-A13 has antiproliferative and anticancer activity. LFM-A13 can be used in cancer-related research.

 

Brand: BCM

 

Target: Polo-like Kinase (PLK); Btk; JAK

 

Solubility: Soluble in DMSO (warmed with 50ºC water bath). Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS07

 

Isomeric SMILES: CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O  

 

InChIKey: UVSVTDVJQAJIFG-UHFFFAOYSA-N  

 

InChI: InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)

 

Attribute
[Chem Name]	2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
[Synonym]	LFM-A13; LFM A13; DDE-28
[CAS No.]	62004-35-7
[MDL No.]	MFCD02179204
[Formula]	C11H8Br2N2O2
[Molecular]	360
[Form]	White powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag